|
Commitments and Contingencies - Additional Information (Detail) (USD $)
|
6 Months Ended |
|
Jun. 30, 2014
|
|
UFRF License Agreements [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
5.00%
|
| Company's obligation to pay from all revenue received from sublicenses |
22.00%
|
| One-time commercialization fee monthly amount for calculation |
$ 5,000
|
| Post-commercialization minimum royalty payments |
50,000
|
| One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount |
2,000,000
|
| One-time additional payment to UFRF as a percentage of total royalties due to UFRF |
10.00%
|
| Commercial sales |
0
|
| Commercialization fees |
0
|
| Minimum annual maintenance payment per license agreement |
10,000
|
| Aggregate minimum annual maintenance payment |
20,000
|
| Quarterly maintenance payment to UFRF under installment plan |
5,000
|
| Termination notice period |
90 days
|
|
Texas A and M University License [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
5.00%
|
| Initial payment to Texas A&M |
5,000
|
| Minimum consideration for the continuation of the license agreement |
15,000
|
| Minimum annual amount to Texas A&M |
100,000
|
| Annual maintenance payment under licensing agreement with Texas A&M |
100,000
|
| Maximum period to cure the breach |
60 days
|
| Termination notice period |
90 days
|
|
Texas A and M University License [Member] | Phase I Clinical Trial [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun.
01,
2015
|
| Milestone payment under licensing agreement |
50,000
|
|
Texas A and M University License [Member] | Phase II Clinical Trial [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun.
01,
2019
|
| Milestone payment under licensing agreement |
100,000
|
|
Texas A and M University License [Member] | Phase III Clinical Trial [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun.
01,
2022
|
| Milestone payment under licensing agreement |
150,000
|
|
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Date of milestone achievement under licensing agreement with Texas A&M |
Jun.
01,
2025
|
| Milestone payment under licensing agreement |
400,000
|
|
Texas A and M University License [Member] | Minimum [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
2.00%
|
|
Probiotics ECC [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
10.00%
|
| Maximum period to cure the breach |
60 days
|
| Number of milestones achieved |
0
|
| Termination notice period |
90 days
|
| Milestone measurement period |
30 days
|
|
Probiotics ECC [Member] | Phase II Clinical Trial [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
2,000,000
|
|
Probiotics ECC [Member] | Phase III Clinical Trial [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
5,000,000
|
|
Probiotics ECC [Member] | Sale Of Licensed Technology [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Milestone payment under licensing agreement |
$ 10,000,000
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Company's obligation to pay from percentage of selling price of product |
25.00%
|
| Company's obligation to pay from all revenue received from sublicenses |
50.00%
|
| Number of shares issued |
4,392,425
|
| Maximum percentage of primary investment securities to investment of shares issued |
10.00%
|
| Number of milestones achieved |
0
|
| Termination notice period |
90 days
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Investigational New Drug Application [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
1.00%
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 2 [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
1.50%
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 3 [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
2.00%
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Filing of First Investigational New Drug Application [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
2.50%
|
|
Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | First Regulatory Approval of Oragenics Product [Member]
|
|
| Commitment And Contingencies [Line Items] |
|
| Percentage of number of shares of common stock equal to Base Shares |
3.00%
|